Azenta's fiscal third quarter was a quiet operational beat wrapped inside a complicated corporate calendar. Third-quarter revenue of $161 million rose 12% from a year ago (9% organic), adjusted EBITDA of $18.5 million expanded roughly 600 basis points sequentially from $7.8 million in the second quarter, and free cash flow ran negative $5 million - typical for a quarter with the company's first full quarter of UK Biocentre integration but lighter than the prior year. Strip out the September 30, 2026 sale of B Medical Systems (closed July 1, 2026) and the print reflects a continuing-operations business that is growing modestly, holding adjusted EBITDA margins near 11%, and lapping a year-ago quarter in which management was still managing through automated-store rework. The headline GAAP operating loss of $4.2 million looks worse than it is, because the 12-month loss-from-continuing-operations line is dominated by a $149 million non-cash goodwill impairment booked in the second quarter. The question the next six months will answer is whether the $59 to $62 million full-year adjusted-EBITDA guide (raised from prior) can compound into something better, or whether the SMS rework and Multiomics restructuring have already given management what they expect to give.